Abstract: A radiotherapeutic immunoconjugate comprising a tumor specific monoclonal antibody, or fragment thereof, and an Auger electron emitting radionuclide, wherein the tumor specific monoclonal antibody or fragment is capable of tumor nucleus localization of the radionuclide and method of using it is disclosed. The radiotherapeutic immunoconjugate is administered in a therapeutically effective amount to patients having or suspected of having a malignancy reactive with the antibody or fragment.

Abstract: A method is set forth for treatment of hypoxic tumors by interstitial injection of oxygen bearing fluorocarbon emulsions directly into the hypoxic zone of the tumor followed by radiation treatment.

Abstract: Process of radioimaging the myocardium of mammals using intravenous injection of radiolabeled lipophilic cations of quaternary ammonium, quaternary phosphonium or quaternary arsonium compounds of the formula ##STR1## where R.sub.1 and R.sub.2 are alkyl or aryl groups, R.sub.3 and R.sub.4 are phenyl or benzyl groups, X is Br.sup.-, I.sup.- or Cl.sup.-, L is I.sup.123, I.sup.125, I.sup.131, Br.sup.77, Br.sup.82 or F.sup.18 and Z is nitrogen, phosphorous or arsenic.

Abstract: High purity phosphorus and phosphorus compounds are prepared by first reacting H.sub.3 PO.sub.4 with a lead compound such as PbO to form Pb.sub.3 (PO.sub.4).sub.2. The Pb.sub.3 (PO.sub.4).sub.2 is reduced with H.sub.2 at a temperature sufficient to form gaseous phosphorus which can be recovered as a high purity phosphorus product. Phosphorus compounds can be easily prepared by reacting the phosphorus product with gaseous reactants. For example, the phosphorus product is reacted with gaseous Cl.sub.2 to form PCl.sub.5. PCl.sub.5 is reduced to PCl.sub.3 by contacting it in the gaseous phase with solid elemental phosphorus. POCl.sub.3 can be prepared by contacting PCl.sub.5 in the gaseous phase with solid P.sub.2 O.sub.5. The general process is particularly suitable for the preparation of radiophosphorus compounds.